Ariane Klein
YOU?
Author Swipe
View article: POS0284 CANAKINUMAB FIRST LINE STEROID FREE TREATMENT IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
POS0284 CANAKINUMAB FIRST LINE STEROID FREE TREATMENT IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS Open
View article: POS1059 EFFICACY OF BIOLOGIC AND JANUS KINASE INHIBITOR TREATMENTS IN FIRST, SECOND, AND SUBSEQUENT COURSES FOR POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS- AN ANALYSIS FROM THE BiKeR registry
POS1059 EFFICACY OF BIOLOGIC AND JANUS KINASE INHIBITOR TREATMENTS IN FIRST, SECOND, AND SUBSEQUENT COURSES FOR POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS- AN ANALYSIS FROM THE BiKeR registry Open
View article: POS1057 TOFACITINIB TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS -DATA FROM THE GERMAN BIKER REGISTRY
POS1057 TOFACITINIB TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS -DATA FROM THE GERMAN BIKER REGISTRY Open
View article: Vergleich der Therapie mit JAK-Inhibitoren bei der juvenilen idiopathischen Arthritis in der klinischen Praxis und in den Zulassungsstudien
Vergleich der Therapie mit JAK-Inhibitoren bei der juvenilen idiopathischen Arthritis in der klinischen Praxis und in den Zulassungsstudien Open
ZUSAMMENFASSUNG Die juvenile idiopathische Arthritis (JIA) ist die häufigste chronisch-entzündliche rheumatische Erkrankung des Kindes- und Jugendalters. Mit der Einführung von Biologika konnte eine erhebliche Verbesserung von Prognose, Ou…
View article: POS0284 COVID-19 SYMPTOMS AND DISEASE COURSE IN GERMAN PEDIATRIC RHEUMATOLOGY PATIENTS REPORTED TO BIKER
POS0284 COVID-19 SYMPTOMS AND DISEASE COURSE IN GERMAN PEDIATRIC RHEUMATOLOGY PATIENTS REPORTED TO BIKER Open
View article: OP0161 24 MONTH RESULTS ON EFFECTIVENESS AND SAFETY OF A COMPARATIVE STUDY OF TOCILIZUMAB VERSUS TUMOUR NECROSIS FACTOR INHIBITION IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
OP0161 24 MONTH RESULTS ON EFFECTIVENESS AND SAFETY OF A COMPARATIVE STUDY OF TOCILIZUMAB VERSUS TUMOUR NECROSIS FACTOR INHIBITION IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS Open
View article: Kawasaki-Syndrom mit Ikterus
Kawasaki-Syndrom mit Ikterus Open
Ein 5 Jahre alter Patient stellte sich mit Fieber seit 6 Tagen, Konjunktivitis und Husten vor. Zudem sind ein dunkler Urin und ein entfärbter Stuhl aufgefallen. Die weitere Eigen- und Familienanamnese war unauffällig. Es bestand ein Kawasa…
View article: POS0287 TOFACITINIB IN JUVENILE IDIOPATHIC ARTHRITIS: FIRST YEAR EXPERIENCE
POS0287 TOFACITINIB IN JUVENILE IDIOPATHIC ARTHRITIS: FIRST YEAR EXPERIENCE Open
Background Tofacitinib is an oral Janus kinase inhibitor recently approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA) aged 2 to Objectives To characterize JIA cohorts tre…
View article: OP0163 GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS – AN UPDATE ON SAFETY AND EFFECTIVENESS FROM THE BIKER REGISTRY
OP0163 GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS – AN UPDATE ON SAFETY AND EFFECTIVENESS FROM THE BIKER REGISTRY Open
Background Golimumab (GOL) is approved for treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years and older. Data on long-term safety of GOL in this indication are limited. Objectives To assess long-term safety…
View article: Prevalence and risk factors of depressive symptoms in children and adolescents with juvenile idiopathic arthritis
Prevalence and risk factors of depressive symptoms in children and adolescents with juvenile idiopathic arthritis Open
Depression is a serious disorder disproportionately affecting people with chronic diseases, yet, to date is rarely recognized comorbidity in pediatric rheumatology clinical routine care. The aim of this study was to investigate the prevale…
View article: Outcome of adult patients with JIA treated with the biosimilar Benepali®: results of the biologic register JuMBO
Outcome of adult patients with JIA treated with the biosimilar Benepali®: results of the biologic register JuMBO Open
Background To analyze therapy adherence, safety, and outcome in adult patients with juvenile idiopathic arthritis (JIA) treated with the etanercept biosimilar Benepali ® (Biogen Inc, Cambridge, USA). Methods Data from the prospective regis…
View article: Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study Open
Objective To assess the medication and disease burden of young adults with juvenile idiopathic arthritis (JIA). Methods Young adults with JIA prospectively followed in the Juvenile Arthritis Methotrexate/Biologics long-term Observation rep…
View article: Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial
Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial Open
ISRCTN69963079.
View article: Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries Open
Objectives Burden of comorbidities are largely unknown in JIA. From 2000, national and international patient registries were established to monitor biologic treatment, disease activity and adverse events in patients with JIA. The aim of th…
View article: Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study Open
Objective Analysis of etanercept biosimilars in pediatric patients with juvenile idiopathic arthritis (JIA) in comparison with the etanercept originator in terms of efficacy and safety. Methods Patients diagnosed with JIA who started treat…
View article: Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany
Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany Open
Objectives This study aimed to investigate the clinical manifestations, course and outcome of SARS-CoV-2 infection among children and adolescents with rheumatic and musculoskeletal diseases (RMD). Due to their underlying disease as well du…
View article: POS0075 SAFETY AND EFFICACY OF GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS - AN UPDATE FROM THE BIKER REGISTRY
POS0075 SAFETY AND EFFICACY OF GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS - AN UPDATE FROM THE BIKER REGISTRY Open
View article: POS1202 EXPERIENCE WITH COVID-19 IN GERMAN PAEDIATRIC RHEUMATOLOGY CENTRES
POS1202 EXPERIENCE WITH COVID-19 IN GERMAN PAEDIATRIC RHEUMATOLOGY CENTRES Open
View article: POS1301 DRUG SURVIVAL OF BIOLOGICS WITH RESPECT TO COMBINATION WITH METHOTREXATE IN TREATMENT OF POLYARTICULAR JIA
POS1301 DRUG SURVIVAL OF BIOLOGICS WITH RESPECT TO COMBINATION WITH METHOTREXATE IN TREATMENT OF POLYARTICULAR JIA Open
View article: OP0165 RISK FOR UVEITIS EVENTS AFTER WITHDRAWAL OF DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN THE TREATMENT OF PATIENTS WITH EXTENDED OLIGOARTHRITIS OR RHEUMATOID FACTOR NEGATIVE POLYARTHRITIS
OP0165 RISK FOR UVEITIS EVENTS AFTER WITHDRAWAL OF DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN THE TREATMENT OF PATIENTS WITH EXTENDED OLIGOARTHRITIS OR RHEUMATOID FACTOR NEGATIVE POLYARTHRITIS Open
View article: OP0163 COMPARATIVE ANALYSIS OF ETANERCEPT BIOSIMILAR AND ORIGINATOR USE IN CLINICAL PRACTICE: DATA FROM THE GERMAN BIKER-REGISTRY
OP0163 COMPARATIVE ANALYSIS OF ETANERCEPT BIOSIMILAR AND ORIGINATOR USE IN CLINICAL PRACTICE: DATA FROM THE GERMAN BIKER-REGISTRY Open
View article: Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis Open
Objectives To determine (i) correlates for etanercept (ETA) discontinuation after achieving an inactive disease and for the subsequent risk of flare and (ii) to analyze the effectiveness of ETA in the re-treatment after a disease flare. Me…
View article: SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases – data from the National Pediatric Rheumatology Database in Germany
SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases – data from the National Pediatric Rheumatology Database in Germany Open
Objectives Due to their underlying disease as well as therapeutic immunosuppression, children and adolescents with rheumatic and musculoskeletal diseases (RMD) may be at higher risk for a severe course or worse outcome of COVID-19, and SAR…
View article: Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry
Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry Open
View article: Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry
Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry Open
View article: Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry Open
Background At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long periods, sometimes ev…
View article: Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BIKER registry
Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BIKER registry Open
Background: At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long periods, sometimes e…
View article: Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BIKER registry
Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BIKER registry Open
Background: At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long periods, sometimes e…
View article: THU0515 SYSTEMIC LUPUS ERYTHEMATOSUS IN CHILDHOOD AND ADOLESCENCE - UPDATE FROM THE NATIONAL PEDIATRIC RHEUMATOLOGY DATABASE
THU0515 SYSTEMIC LUPUS ERYTHEMATOSUS IN CHILDHOOD AND ADOLESCENCE - UPDATE FROM THE NATIONAL PEDIATRIC RHEUMATOLOGY DATABASE Open